AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
AstraZeneca
Study ID
NCT05850234
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD0120 — BIOLOGICAL
    AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.

Study Details

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Key Dates

Start date
Jul 20, 2023
Status verified
May 2026
Primary completion
Aug 31, 2027
Completion
Nov 14, 2028

Study Design

Enrollment
182 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AZD0120
    AZD0120 will be administered by infusion

Primary Outcome Measure

Phase 1b: Adverse Events (AEs) [ Time Frame: Through study completion, a minimum of 2 years. ]

Central Contacts

Locations (36)

FacilityCityStateZIPSite coordinators
Research SiteBirminghamAlabama35233-
Research SitePhoenixArizona85054-
Research SiteLa JollaCalifornia92037-
Research SiteLos AngelesCalifornia90095-
Research SiteSan FranciscoCalifornia94143-
Research SiteAuroraColorado80045-
Research SiteDenverColorado80218-
Research SiteJacksonvilleFlorida32224-
Research SiteMiamiFlorida33136-
Research SiteTampaFlorida33612-
Research SiteAtlantaGeorgia30322-
Research SiteChicagoIllinois60637-
Research SiteIowa CityIowa52242-
Research SiteBostonMassachusetts02114-
Research SiteBostonMassachusetts02215-
Research SiteAnn ArborMichigan48109-
Research SiteDetroitMichigan48202-
Research SiteMinneapolisMinnesota55455-
Research SiteRochesterMinnesota55905-
Research SiteOmahaNebraska68198-
Research SiteHackensackNew Jersey07601-
Research SiteBuffaloNew York14203-
Research SiteNew YorkNew York10065-
Research SiteStony BrookNew York11794-
Research SiteCharlotteNorth Carolina28204-
Research SiteDurhamNorth Carolina27705-
Research SiteNashvilleTennessee37203-
Research SiteNashvilleTennessee37232-
Research SiteAustinTexas78704-
Research SiteDallasTexas75390-
Research SiteHoustonTexas77030-
Research SiteSalt Lake CityUtah84112-
Research SiteCharlottesvilleVirginia22908-
Research SiteEdmondsWashington98026-
Research SiteSeattleWashington98109-
Research SiteMilwaukeeWisconsin53226-

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Research Site· Birmingham, ALResearch Site· Phoenix, AZResearch Site· La Jolla, CAResearch Site· Los Angeles, CAResearch Site· San Francisco, CAResearch Site· Aurora, CO

Related Studies